Dishman Carbogen Amcis Ltd has scheduled a Board meeting on December 27, 2025, to evaluate a proposal for raising funds through the private placement of Non-Convertible Debentures (NCDs). The move aims to strengthen its financial position and support ongoing business expansion, subject to necessary regulatory approvals.
Dishman Carbogen Amcis Limited, a pharmaceutical and chemical development company, has notified the exchanges that its Board of Directors will convene on Saturday, December 27, 2025, to deliberate on a fund-raising proposal via Non-Convertible Debentures (NCDs).
According to the company’s filing with the BSE and NSE, the proposed issuance will be executed through private placement, a route typically favored for tapping qualified institutional investors efficiently. The exercise will be subject to all statutory and regulatory approvals required under applicable laws.
While the company has not yet disclosed the quantum or structure of the NCD issue, the move signals its intent to bolster liquidity and maintain a healthy capital mix amid a dynamic business environment. Dishman Carbogen, engaged in providing development and manufacturing services to the pharmaceutical sector, continues to explore routes for sustainable growth and operational optimization.
Key Highlights / Notable Updates
-
Board Meeting Date: December 27, 2025
-
Purpose: To consider fund-raising through issuance of NCDs via private placement
-
Objective: Strengthening financial flexibility and supporting expansion initiatives
-
Approval: Subject to requisite statutory and regulatory clearances.
Source: Corporate filings with BSE and NSE (official exchange announcements)